Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218133

SCHEMBL23218133

SCHEMBL23218133

CCOC(=O)c1coc2c(COc3ccc(F)cc3)cc(Br)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP1 P03956 4/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ KDM4E B2RXH2 4/20 0.39
▸ PPARA Q07869 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ GAA P10253 3/20 0.38
▸ POLB P06746 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ MAOB P27338 2/20 0.38
▸ DAO P14920 1/20 0.38
▸ GABRA1 P14867 1/20 0.38
▸ GABRB1 P18505 1/20 0.38
▸ GABRA3 P34903 1/20 0.38
▸ GABRB2 P47870 1/20 0.38
▸ MAPT P10636 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23219210 0.89 TSHR (0.45) ALDH1A1KDM4EHSD17B10SMN1; SMN2L3MBTL1
SCHEMBL29853260 0.80 ALDH1A1 (0.42) ALDH1A1KDM4EGAASMN1; SMN2LMNA
SCHEMBL23218838 0.80 ALDH1A1 (0.42) ALDH1A1KDM4EGAASMN1; SMN2LMNA
SCHEMBL23218182 0.80 MAOB (0.38) MMP1ALDH1A1KDM4EPPARAHPGD
SCHEMBL29852673 0.80 MAOB (0.38) MMP1ALDH1A1KDM4EPPARAHPGD
SCHEMBL29591344 0.78 DAO (0.40) MMP1ALDH1A1PPARAHSD17B10GAA
SCHEMBL23218681 0.78 DAO (0.40) MMP1ALDH1A1PPARAHSD17B10GAA
SCHEMBL29852641 0.77 GABRA1 (0.42) ALDH1A1KDM4EGAASMN1; SMN2LMNA
SCHEMBL23218592 0.77 GABRA1 (0.42) ALDH1A1KDM4EGAASMN1; SMN2LMNA
SCHEMBL23218947 0.76 ALDH1A1 (0.45) ALDH1A1KDM4EGAASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY ACADIA PHARMACEUTICALS INC. 2016-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY SLC6A4, HTR4, GPR34 MMP1 3003/4885ALDH1A1 3075/4885KDM4E 1720/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MMP1 1357/4885ALDH1A1 2667/4885KDM4E 4172/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MMP1 1045/4885ALDH1A1 3142/4885KDM4E 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.